Quality Management System requirement under 21 CFR Part 820 and EU GMP Annex 1 highlight the necessity of having a comprehensive understanding of CQAs and CPPs to meet quality objectives.

Key Regulations and Guidelines

• FDA Guidance for Industry: Q8 (R2) Pharmaceutical Development
• EMA Quality Guidelines
• ICH Q8, Q9, and Q10
• 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals
• EU GMP Annex 1: Manufacture of Sterile Medicinal Products

Documentation

Proper documentation is critical to the success of defining and justifying CQAs and CPPs. This documentation serves as both a foundation for regulatory submissions and as a reference for internal quality management. The primary documents involved include:

1. Quality Target Product Profile (QTPP)

The QTPP outlines the quality characteristics that the product should possess to ensure its safety and efficacy. This document acts as the blueprint for identifying relevant CQAs.

2. Identification of CQAs

CQAs are the physical, chemical, biological, or microbiological properties or characteristics that must be controlled to ensure product quality. It is essential to document the rationale for selecting specific CQAs based on their impact on product quality. Consider using tools such as risk assessments or statistical process control (SPC) to justify these attributes.

3. Definition of CPPs

CPPs are the process parameters whose variability can impact CQAs. These parameters need to be documented thoroughly including how they will be monitored and controlled during manufacturing, particularly when utilizing risk management tools like Failure Mode and Effects Analysis (FMEA).

4. Control Strategy Document

The control strategy is a comprehensive document that integrates QTPP, CQAs, and CPPs, detailing the manufacturing processes and controls employed to ensure that CQAs are consistently met. This document should also encompass the methodologies utilized to measure and analyze CQAs.

Review and Approval Flow

The review and approval of CQAs and CPPs typically occur during the submission process, whether it’s a New Drug Application (NDA), Biologics License Application (BLA), or a Marketing Authorization Application (MAA) in the US, EU, and UK respectively.

1. Pre-Submission Activities

Prior to submission, companies should conduct internal reviews to ensure that all CQAs and CPPs have been adequately defined and documented. Performing preliminary risk assessments can assist in identifying critical areas that may raise questions during agency evaluations.

2. Submission to Regulatory Authorities

During submission, include detailed information about the identified CQAs, CPPs, and overall control strategy in both the Quality section of the application and the relevant section of the technical file. For example, in the US, this is specified under 21 CFR 314.50, and in Europe under Directive 2001/83/EC.

3. Agency Review Process

Upon submission, regulatory agencies will evaluate the documentation provided. Key aspects that agencies focus on include how well the documentation justifies the criticality of selected CQAs and CPPs, the rationale behind the control strategy, and the adequacy of the risk assessment conducted.

Common Deficiencies

Despite the rigor employed in establishing CQAs and CPPs, agencies frequently identify certain deficiencies during regulatory reviews. Understanding these common pitfalls can assist professionals in avoiding typical errors.

1. Inadequate Justification of CQAs and CPPs

Often, submissions fail due to insufficient justification or connection between CQAs and CPPs and the Quality Target Product Profile. Companies should ensure that every CQA is backed by appropriate scientific rationale and data.

2. Lack of Comprehensive Risk Assessment

A frequent shortcoming is an incomplete risk assessment. It is vital to employ systematic risk assessment tools to ensure that all potential risks to CQAs have been evaluated and that appropriate controls are in place to mitigate those risks.

3. Poor Documentation Practices

Agency reviewers often cite poorly organized or incomplete documentation as a significant deficiency. All documents relating to CQAs, CPPs, and the overall control strategy should be meticulously organized, clear, and concise, with explanations readily available for agency inquiries.

Regulatory Affairs-Specific Decision Points

When to File as Variation vs. New Application

One of the critical decisions in Regulatory Affairs is determining whether a change warrants filing as a new application or as a variation. This decision can be influenced by the nature of CQAs and CPPs.

• New Application: If the change results in a fundamentally different product or alters the manufacturing process in a way that may affect the safety or efficacy of the drug, it should be submitted as a new application.
• Variation: Modifications that enhance the understanding of the product without changing its overall profile, such as minor adjustments in CPPs, may be filed as variations.

How to Justify Bridging Data

Bridging data may be needed when transitioning from small-scale to large-scale production or when introducing new methodologies affecting CQAs or CPPs. Justifying bridging data should include:

• Rationale for bridging studies and their relevance to CQAs and CPPs.
• Results from scaled studies demonstrating equivalency or improved effectiveness.
• An increase in control over CPPs that leads to enhanced product quality.

Conclusion

Defining CQAs and CPPs using QbD principles is a crucial component of a comprehensive Control Strategy. By adhering to regulatory guidelines and employing systematic documentation practices, professionals in Regulatory Affairs can ensure that their applications stand up to the scrutiny of regulatory bodies. Understanding the interplay between CQAs and CPPs, along with established decision points in filing, can significantly enhance the chance of regulatory approval while supporting the goal of delivering high-quality pharmaceutical products.